title: Selection of ideal candidates for neuromodulation in refractory overactive bladder.
abstract: Sacral neuromodulation is a minimally invasive, reversible treatment option that has been approved by the US Food and Drug Administration for patients with urgency/frequency and urge incontinence. While long-term success rates are high, the high treatment cost and the need for operative revision or explantation in cases of failure make the selection of ideal candidates particularly important. Because predictive factors for success and the exact mechanism of action are not known, physicians must rely on a preimplantation test procedure, either in the office or in the operating room, to select patients for implantation of a pulse generator. In this paper, we review the recent literature on performing a test procedure with both temporary and permanent leads and the selection of optimal candidates for sacral neuromodulation therapy.
authors.affiliation: Department of Urology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Kacker
authors.forename: Anurag K
authors.initials: AK
authors.lastname: Das
mesh_terms: D000328:Adult; D004599:Electric Stimulation Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D018579:Patient Selection; D053201:Urinary Bladder, Overactive / Q000628:therapy*
references.citation: World J Urol. 1998;16(5):313-21
references.pmid: 9833310
references.citation: J Urol. 2000 Mar;163(3):881-3
references.pmid: 10687999
references.citation: J Urol. 2006 Mar;175(3 Pt 1):835-41
references.pmid: 16469561
references.citation: Urology. 2002 May;59(5 Suppl 1):61-7
references.pmid: 12007524
references.citation: BJU Int. 2008 Sep;102(7):774-9
references.pmid: 18616691
references.citation: Urology. 2004 Jul;64(1):62-8
references.pmid: 15245937
references.citation: Urol Clin North Am. 2005 Feb;32(1):65-9
references.pmid: 15698878
references.citation: J Urol. 1999 Aug;162(2):352-7
references.pmid: 10411037
references.citation: J Urol. 2006 Jun;175(6):2178-80; discussion 2180-1
references.pmid: 16697833
references.citation: BJU Int. 2007 Jan;99(1):107-10
references.pmid: 16956350
references.citation: Neurourol Urodyn. 2008;27(1):28-33
references.pmid: 17563110
references.citation: J Urol. 2007 Nov;178(5):2029-34
references.pmid: 17869298
references.citation: J Urol. 1994 Dec;152(6 Pt 1):2071-5
references.pmid: 7966677
references.citation: Eur Urol. 2005 May;47(5):660-5
references.pmid: 15826759
references.citation: Ann Neurol. 2010 Jan;67(1):74-84
references.pmid: 20186953
references.citation: Eur Urol. 2004 May;45(5):649-54
references.pmid: 15082209
references.citation: J Urol. 2010 Jan;183(1):173-6
references.pmid: 19913835
references.citation: J Urol. 2003 Apr;169(4):1369-73
references.pmid: 12629364
references.citation: Neurourol Urodyn. 2002;21(2):167-78
references.pmid: 11857671
references.citation: Urol Int. 2010;84(3):245-53
references.pmid: 20389150
references.citation: Urology. 2000 Dec 4;56(6 Suppl 1):87-91
references.pmid: 11114569
references.citation: Int Urogynecol J Pelvic Floor Dysfunct. 2008 Apr;19(4):553-7
references.pmid: 17925994